SRA515

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca, GSK

Drug class:

BET inhibitor, BRD4 inhibitor

Related drugs:

‹

›

MUS81 overexpression	Gastric Cancer	MUS81 overexpression	Gastric Cancer	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D
RB1 deletion	Ovarian Cancer	RB1 deletion	Ovarian Cancer	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D
RB1 deletion	Ovarian Cancer	RB1 deletion	Ovarian Cancer	palbociclib + SRA515 Sensitive: D – Preclinical palbociclib + SRA515 Sensitive : D	palbociclib + SRA515 Sensitive: D – Preclinical palbociclib + SRA515 Sensitive : D

Associations
(3)